Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 885277
                    [Title] => Sponges and humans... alike in many ways
                    [Summary] => 
In November 2010, a new drug for cancer named Halaven (generic name eribulin mesylate) was approved by the US FDA (Food and Drug Administration).

                    [DatePublished] => 2012-12-13 00:00:00
                    [ColumnID] => 135735
                    [Focus] => 0
                    [AuthorID] => 1339989
                    [AuthorName] => Gisela Padilla-Concepcion, PhD
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 740509
                    [Title] => Breast cancer:  Progress & promise in 2011
                    [Summary] => 
The field of breast cancer has been a model for innovation and discovery.
                    [DatePublished] => 2011-10-25 00:00:00
                    [ColumnID] => 133436
                    [Focus] => 0
                    [AuthorID] => 1778504
                    [AuthorName] => Tyrone M. Reyes M.D.
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => http://img714.imageshack.us/img714/6105/lif1thumba.jpg
                )

        )

)

HALAVEN

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 885277
                    [Title] => Sponges and humans... alike in many ways
                    [Summary] => 
In November 2010, a new drug for cancer named Halaven (generic name eribulin mesylate) was approved by the US FDA (Food and Drug Administration).

                    [DatePublished] => 2012-12-13 00:00:00
                    [ColumnID] => 135735
                    [Focus] => 0
                    [AuthorID] => 1339989
                    [AuthorName] => Gisela Padilla-Concepcion, PhD
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 740509
                    [Title] => Breast cancer:  Progress & promise in 2011
                    [Summary] => 
The field of breast cancer has been a model for innovation and discovery.
                    [DatePublished] => 2011-10-25 00:00:00
                    [ColumnID] => 133436
                    [Focus] => 0
                    [AuthorID] => 1778504
                    [AuthorName] => Tyrone M. Reyes M.D.
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => http://img714.imageshack.us/img714/6105/lif1thumba.jpg
                )

        )

)

abtest

Sponges and humans... alike in many ways

By Gisela Padilla-Concepcion, PhD | December 13, 2012 - 12:00am

In November 2010, a new drug for cancer named Halaven (generic name eribulin mesylate) was approved by the US FDA (Food and Drug Administration).

Science and Environment

Breast cancer: Progress & promise in 2011

By Tyrone M. Reyes M.D. | October 25, 2011 - 12:00am

The field of breast cancer has been a model for innovation and discovery.

Health And Family